2018). To date, however, no clinical studies have convincingly confirmed the effect of pharmacological treatment against AAA progression. Hyperlipidemia and renin–angiotensin activation are known to be risk factors for AAA progression (Erbel et al. 2014), but AAA expansion was not associated with hypercholesterolemia in clinical studies (Lindholt et al. 2001; Baxter et al. 2008). The efficacy of renin–angiotensin system‐inhibiting drugs also remains controversial (Malekzadeh et al. 2013; Salata et al. 2018). The gene discussed is REN; the disease is triple-A syndrome.